Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GlaxoSmithKline (GSK) and Daiichi Sankyo have announced a strategic alliance and formed a vaccine Joint Venture (JV), named Japan Vaccine.
Subscribe to our email newsletter
The JV is responsible for development and commercial rights of prophylactic vaccines.
The companies will invest equally in the JV and the transaction is expected to be completed in third quarter 2012, subject to local regulatory approvals.
Japan Vaccine will contribute to improving access to vaccines in Japan, introduce new vaccines, bring together the technologies and products of parent companies to create more convenient combination vaccines.
The new JV will provide evidence based information and ensure stable supply of vaccines, the companies said.